RadNet to Host Men's Health Webinar on June 13, 2026

Rhea-AI Summary

RadNet (NASDAQ: RDNT) will host a free public Men’s Health webinar on Saturday, June 13, 2026, during National Men’s Health Month.

Leading radiologists will discuss coronary artery disease, prostate cancer and lung cancer, focusing on risk factors, screening criteria and the role of diagnostic imaging in early detection.

News Market Reaction – RDNT

+2.73%

+2.73% Session close to close

In the May 28 session, RDNT gained 2.73%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights RadNet’s use of its network of over 440 centers and imaging modalities ...

Analysis

This announcement highlights RadNet’s use of its network of over 440 centers and imaging modalities such as cardiac CT, prostate MRI and low-dose CT to support men’s health education and early detection. It complements earlier updates on financial growth and AI collaborations, underscoring a strategy that blends scale, technology and patient outreach. Investors may watch for how such events translate into screening volumes, center utilization and sustained demand for advanced imaging services.

Key Figures

Imaging centers network: over 440 centers Cardiovascular disease prevalence: more than 52% of men over 20 Prostate cancer risk: 1 in 8 men +5 more

8 metrics

Imaging centers network over 440 centers RadNet outpatient imaging centers described in article

Cardiovascular disease prevalence more than 52% of men over 20 Men living with some form of cardiovascular disease

Prostate cancer risk 1 in 8 men Lifetime risk of prostate cancer in men

Genetic prostate cancer risk more than 50% of risk Portion of prostate cancer risk tied to genetics

Early-stage lung cancer diagnoses 28.1% of cases Lung cancer cases diagnosed at an early stage in men

Suggested screening age heart disease 40 years Suggested age to discuss heart disease screening

Suggested screening age prostate cancer 45 years Suggested age to discuss prostate cancer screening

Suggested screening age lung cancer 50 years Suggested age to discuss lung cancer screening

Historical Context

5 past events · Latest: May 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 10	Q1 2026 earnings	Positive	-3.9%	Record Q1 2026 revenue and guidance raised for revenue, EBITDA and free cash flow.
Apr 30	Boise joint venture	Positive	+0.5%	New joint venture in Boise with projected annual revenue of about $30 million.
Apr 28	Earnings call date	Neutral	+0.2%	Announcement of date and details for Q1 2026 financial results conference call.
Apr 16	AI collaboration	Positive	+0.5%	GE HealthCare expanded global access to DeepHealth AI-powered breast screening tools.
Mar 17	Conference presentation	Neutral	-0.7%	CFO presentation at KeyBanc healthcare forum with live and archived webcasts.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive strategic and financial updates have not always produced positive next-day moves, as seen with record Q1 results drawing a negative reaction.

Recent Company History

Over the last few months, RadNet reported record Q1 2026 results with revenue of $575.6 million and raised guidance, yet the stock fell 3.94% the next day. Strategic moves included a Boise joint venture projected at $30 million in annual revenue and an expanded AI breast screening collaboration with GE HealthCare, both followed by modest gains. Conference-related announcements saw only slight moves. Today’s men’s health webinar news fits into a pattern of outreach and brand-building alongside ongoing expansion and AI initiatives.

Key Terms

coronary artery disease, prostate cancer, lung cancer, low-dose CT, +2 more

6 terms

coronary artery disease medical

"physicians addressing coronary artery disease, prostate cancer and lung cancer"

Coronary artery disease is a condition in which the blood vessels that supply the heart become narrowed or blocked by fatty buildup, reducing oxygen-rich blood flow and making the heart work harder. For investors, it matters because the condition drives demand for medications, medical devices, diagnostics and procedures, can affect healthcare spending and payer policies, and influences the financial prospects of companies involved in cardiovascular care—similar to how a clogged pipe changes maintenance and replacement needs.

prostate cancer medical

"addressing coronary artery disease, prostate cancer and lung cancer"

A disease in which cells in the prostate gland grow uncontrollably and can invade nearby tissue or spread to other parts of the body, often affecting urinary function and quality of life. For investors, it matters because diagnosis methods, prescription drugs, surgical tools and follow-up care create a sizable and predictable market; news about trial results, regulatory approvals or changes in screening can quickly shift demand and company valuations—like a fault in a key machine part prompting a wave of repairs and replacements.

lung cancer medical

"prostate cancer and lung cancer. The clinical case for increased"

Lung cancer is a disease where abnormal cells in the lungs grow uncontrollably, forming masses that can impair breathing and spread to other parts of the body. It matters to investors because rates of diagnosis, advances in treatments or diagnostic tools, and regulatory approvals can rapidly change demand, costs and revenue for drugmakers, device makers and healthcare providers—much like a major product shift reshapes a company’s financial outlook.

low-dose CT medical

"will present on low-dose CT for lung cancer screening and its benefits"

Low-dose CT is a medical imaging scan that uses X-rays like a regular CT but reduces the radiation per scan so it’s closer to the dose of a strong X‑ray rather than a full CT. For investors, it matters because lower radiation makes routine screening programs (for example, lung screening) safer and more acceptable, which can increase demand for scanners, influence reimbursement and regulatory approval, and affect healthcare costs and device makers’ revenues.

cardiac CT medical

"services, including cardiac CT, prostate MRI and low-dose lung CT screening"

Cardiac CT is a noninvasive imaging scan that uses X-rays and computers to create detailed pictures of the heart and its blood vessels, like a high-resolution map or camera for the heart. Investors care because wider use affects demand for scanners, software, contrast agents and hospital services, can change patient referral patterns, and influences reimbursement and regulatory decisions that drive revenue and cost trends in healthcare companies.

prostate MRI medical

"including cardiac CT, prostate MRI and low-dose lung CT screening"

Prostate MRI is a detailed, noninvasive imaging scan that creates clear pictures of the prostate gland to detect tumors, inflammation, or other abnormalities—think of it as a high-resolution map doctors use to find trouble spots. It matters to investors because wider use, better scanners, or improved interpretation software can change demand for medical equipment, diagnostic services, and reimbursed procedures, affecting revenue and regulatory risk across healthcare and med‑tech companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Free public event during National Men’s Health Month features leading physicians addressing coronary artery disease, prostate cancer and lung cancer 

LOS ANGELES, May 28, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of over 440 outpatient imaging centers and a premier developer of radiology digital health solutions, today announced it will host a free webinar for patients and the general public on Saturday, June 13, 2026, in recognition of National Men’s Health Month. The event will feature presentations by radiologists on three of the most significant health conditions affecting American men today: coronary artery disease, prostate cancer and lung cancer.

The clinical case for increased attention to men's health is well established. Heart disease remains the leading cause of death for American men, with more than 52% of men over the age of 20 living with some form of cardiovascular disease.¹ Prostate cancer — the second most commonly diagnosed cancer in men globally — affects 1 in 8 men, with more than 50% of risk tied to genetics.² Lung cancer remains the leading cause of cancer-related death among men, yet only 28.1% of cases are diagnosed at an early stage, when treatment options are most effective.³ Across all three conditions, early detection is critical for improved outcomes. Men should talk to their physicians about potentially starting screening at 40 years for heart disease, 45 years for prostate cancer and 50 years for lung cancer.

The June 13 webinar will provide patients with accessible, physician-led education on risk factors, screening criteria and the role of diagnostic imaging in early detection. Attendees will also have the opportunity to participate in a live question and answer discussion with the physicians. Speakers include:

• Michael G. Coords, MD, FSCCT, Medical Director, California, will present on coronary artery disease, offering a clinical overview of risk identification and the imaging tools available to detect disease before a cardiac event occurs.
• Randall Stenoien, MD, Medical Director, Texas, will present on advances in prostate MRI and AI for early detection of prostate cancer.
• Evan Kaminer, MD, FACR, Medical Director, New York, will present on low-dose CT for lung cancer screening and its benefits for high-risk asymptomatic patients.
  
  

“Men's health is one of the most underdiscussed areas of preventive care, and we built this event specifically to close that gap,” said Gregory Sorensen, MD, Executive Vice President and Chief Strategy Officer, RadNet. “At RadNet, we believe that access to the latest information is just as important as access to the imaging technology itself. Early detection can save lives, and events like this are how we put that belief into action.”

RadNet operates more than 435 outpatient imaging centers across 11 states, providing patients with convenient access to advanced diagnostic imaging services, including cardiac CT, prostate MRI and low-dose lung CT screening. The company's AI-enhanced imaging technology and network of expert radiologists deliver accurate, timely results to support clinical decision-making and, where applicable, early intervention.

Event Details
The webinar is free to attend and open to all.

• Date: Saturday, June 13, 2026
• Time: 10-11 a.m. PDT // 1-2 p.m. EDT
• Register: www.radnet.com/webinars/mens-health
  
  

About RadNet, Inc. 
RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue.  RadNet has a network of owned and/or operated outpatient imaging centers.  RadNet’s imaging center markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia.  In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally.  Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 11,000 team members.  Learn more at radnet.com. 

These presentations are provided for educational and informational purposes only and do not constitute medical advice, diagnosis or treatment recommendations. Clinical decisions should be based on the independent judgment of qualified healthcare professionals, taking into account the specific circumstances of each patient.

RadNet Media Contact 
Jane Mazur 
Senior Vice President, Corporate Communications 
+1 585-355-5978 
jane.mazur@radnet.com  

References

      1)   Martin SS, et al., “2025 Heart Disease & Stroke Statistical Update Fact Sheet Males & Cardiovascular Diseases.” American Heart Association. January 2025.

      2)   “Key Statistics for Prostate Cancer.” American Cancer Society. January 2026.

      3)   “New Report: Lung Cancer Advancements Are Saving More Lives Than Ever, but Funding Cuts May Hinder Progress.” American Lung Association. November 2025.

FAQ

What is the RadNet (RDNT) Men’s Health webinar on June 13, 2026 about?

The RadNet Men’s Health webinar will cover coronary artery disease, prostate cancer and lung cancer. According to RadNet, radiologists will explain risk factors, screening criteria and how diagnostic imaging supports early detection and better outcomes for men’s health.

When is the RadNet (RDNT) Men’s Health webinar and what is the time?

The RadNet Men’s Health webinar takes place on Saturday, June 13, 2026. According to RadNet, it runs from 10–11 a.m. PDT and 1–2 p.m. EDT, offering a one-hour, physician-led online education session.

Is the RadNet (RDNT) Men’s Health webinar on June 13, 2026 free to attend?

Yes, the RadNet Men’s Health webinar is free and open to the public. According to RadNet, anyone interested in coronary artery disease, prostate cancer and lung cancer screening can register online and join the live physician presentations and Q&A.

How can I register for the RadNet (RDNT) Men’s Health webinar in June 2026?

To register, visit www.radnet.com/webinars/mens-health and complete the online form. According to RadNet, registration gives access to the live webinar, including presentations by radiologists and a real-time question and answer session.

Which doctors will speak at the RadNet (RDNT) Men’s Health webinar on June 13, 2026?

Speakers include Dr. Michael G. Coords on coronary artery disease, Dr. Randall Stenoien on prostate MRI and AI, and Dr. Evan Kaminer on low-dose CT lung screening. According to RadNet, each will present clinical insights and imaging-focused guidance.

What men’s health screening ages are highlighted in the RadNet (RDNT) webinar?

The webinar highlights talking to physicians about screening at 40 for heart disease, 45 for prostate cancer and 50 for lung cancer. According to RadNet, early detection with appropriate imaging can improve clinical outcomes for men at different risk stages.